Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML

de Botton, S., Cluzeau, T., Vigil, C., Cook, R. J., Rousselot, P., Rizzieri, D. A., Liesveld, J. L., Fenaux, P., Braun, T., Banos, A., Jurcic, J. G., Sekeres, M. A., Savona, M. R., Roboz, G. J., Bixby, D., Madigan, K., Volkert, A., Stephens, K., Kang-Fortner, Q., … Stein, E. M. (2023). Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML. Blood Advances, 7(9), 1858–1870. https://doi.org/10.1182/bloodadvances.2022008806
Authors:
Stéphane de Botton
Thomas Cluzeau
Carlos Vigil
Rachel J Cook
Philippe Rousselot
David A Rizzieri
Jane L Liesveld
Pierre Fenaux
Thorsten Braun
Anne Banos
Joseph G Jurcic
Mikkael A Sekeres
Michael R Savona
Gail J Roboz
Dale Bixby
Kate Madigan
Angela Volkert
Kristin Stephens
Qing Kang-Fortner
Kristen Baker
Sofia Paul
Michael McKeown
John Carulli
Matthew Eaton
Graeme Hodgson
Christopher Fiore
Michael J Kelly
David A Roth
Eytan M Stein
Affiliated Authors:
Joseph G Jurcic
Columbia Affiliation:
Subjects:
Acute Myeloid Leukemia (OpenAlex Topic)
Role of Retinoic Acid in Biological Processes (OpenAlex Topic)
Epidemiology and Treatment of Childhood Leukemia (OpenAlex Topic)
Leukemia, Myeloid, Acute (MeSH)
Leukemia, Promyelocytic, Acute (MeSH)
Myelodysplastic Syndromes (MeSH)
elink
Publication Type:
Article
Unique ID:
10.1182/bloodadvances.2022008806
PMID:
36477975
DOI:
10.1182/bloodadvances.2022008806
Journal:
Blood Advances
Publication Date:
Data Source:
PubMed
Source Link:
View PubMed Record
View Scopus Record
View OpenAlex Record

Record Created: